REGENERON PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31)
REGENERON PHARMACEUTICALS, INC. (REGN) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) of $1.55 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-12.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses · last filed 2015-02-12
- REGENERON PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2014-12-31 was $411.00K.
- REGENERON PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2014-09-30 was $771.00K.
- REGENERON PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2014-06-30 was -$146.00K.
- REGENERON PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for the quarter ending 2014-03-31 was $515.00K.
- REGENERON PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for fiscal 2014 was $1.55M, a 246.98% increase from fiscal 2013.
- REGENERON PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for fiscal 2013 was $447.00K, a 36.32% decline from fiscal 2012.
- REGENERON PHARMACEUTICALS, INC. available-for-sale securities, continuous unrealized loss position, aggregate loss (deprecated 2018-01-31) for fiscal 2012 was $702.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 3 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 6 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 9 month | Available-for-sale Securities, Continuous Unrealized Loss Position, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2014-12-31 | $411.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $1.18M derived: sum of 2 quarters · filed 2015-02-12 | $1.04M derived: sum of 3 quarters · filed 2015-02-12 | $1.55M 10-K · filed 2015-02-12 |
| 2014-09-30 | $771.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $625.00K derived: sum of 2 quarters · filed 2014-11-04 | $1.14M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | -$146.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $369.00K 10-Q · filed 2014-08-05 | ||
| 2014-03-31 | $515.00K 10-Q · filed 2014-05-08 | |||
| 2013-12-31 | $447.00K 10-K · filed 2015-02-12 | |||
| 2012-12-31 | $702.00K 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |